An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Breast Cancer
Both
Breast Cancer
Trial Information
An Ambispective, Non Interventional Study of 2 Cohorts (Triple Negative or HR+) of Patients With HER2- Metastatic or Locally Advanced Breast Cancer Treated With Avastin® (Bevacizumab) 1st Line for at Least 12 Months and Without Progression for at Least 12 Months.
Inclusion Criteria:
- Adult patients, >/=18 years of age
- HER2-metastatic breast cancer or locally advanced breast cancer
- Patients with Avastin as first line therapy administered for at least 12 months
- Patients without disease progression after the beginning of Avastin treatment for at
least 12 months
Exclusion Criteria:
- Patients not willing to give informed consent
Type of Study:
Observational
Study Design:
Observational Model: Cohort
Outcome Measure:
Patient demographics
Outcome Time Frame:
18 months
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
France: Ministry of Health
Study ID:
ML27760
NCT ID:
NCT01461044
Start Date:
September 2011
Completion Date:
December 2013
Related Keywords:
- Breast Cancer
- Breast Neoplasms
Name | Location |
|---|
